AI Recruitment for Gastroenterologists

curved-bar.jpg

Computational Gastroenterology Can Accelerate Clinical Trials and Reduce Administrative Burden

Meet Amy

Amy was diagnosed with Crohn's disease last year and is getting worse despite being on standard of care medicines. She has persistent stomach pain, diarrhea, and fatigue. 

1.png
2.png

The Gastroenterologist 

Amy's gastroenterologist wants to find the best treatment options for her. She is currently receiving steroids and an approved biologic. 

dotted-line.png

Considering all the options… 

One of the things that Amy's gastroenterologist has to decide is if she should try another biologic or if Amy is a good candidate for a clinical trial. Making this decision is a multifactorial and highly complex process that involves knowing Amy's entire clinical picture as well as the eligibility criteria of many trials. 

3.png
dotted-line-flip_edited_edited_edited.png
4.png

The clinical trial 

Clinical trials are conducted to verify efficacy and safety of new therapies and help the broader patient population live healthier lives. For Amy, inclusion in a trial can help her access novel treatments not yet available to the public.

dotted-line.png

Our Technology 

Matching patients to the right trial is a complex process, complicated further by the need for accurate assessment of endoscopic presentation. We have developed algorithms to assist gastroenterologists in understanding disease severity. Our technology can tie together other clinical data points to reduce clinical and administrative burden in matching the right patient to the right trial. 

5.png
dotted-line-flip_edited_edited_edited.png

Iterative Scopes is developing powerful, AI-driven computer algorithms to support clinicians as we seek to improve the processes for identifying and enrolling eligible patients in IBD clinical trials.

How does it work?

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The Problem

 

In IBD, the variability and subjectivity of endoscopic disease scoring makes the identification of patients who are eligible for clinical trials a time-consuming challenge for clinicians.

The process of identifying eligible patients for clinical trial pre-screening places a significant burden on clinical research teams, as it requires searching through individual patient clinical data and endoscopy reports to determine if they meet a given trial’s multiple inclusion and exclusion criteria. 

Manual centralized endoscopy readings are standard in IBD clinical trials, but these are highly dependent on readers’ training and levels of experience and therefore subjective. Manual endoscopy is also used to score disease severity for UC and CD patients, which gastroenterologists use to determine patient eligibility for clinical trials. 

As a result, misclassification of disease severity is a challenge, as is the need for multiple endoscopies. Eligible patients often decide not to participate in clinical trials because of the burden of additional colonoscopies, or patients thought to be eligible based on a subjective reading may be determined ineligible after undergoing an ultimately unnecessary pre-screening colonoscopy.

Automated Disease Severity Scoring 

Iterative Scopes uses computational algorithms integrated with existing colonoscopy imagery and videos to determine clinical trial eligibility. The company’s computational software automates calculation of a patient’s minimal threshold (minimum) score of disease severity, as measured by the Mayo Endoscopic Score (MES) as an aid in determining their qualification for pre-screening for IBD clinical trials.

These threshold scores can help gastroenterologists more quickly and more accurately identify eligible patients for clinical trials and also eliminate the need for repeated endoscopies, which can discourage patients from participating in clinical trials.  

Patients who are referred to pre-screening for clinical trials by gastroenterologists using Iterative Scopes technology are also much more likely to meet a pharmaceutical sponsor’s inclusion and exclusion criteria, and therefore are much less likely to undergo an ultimately unnecessary colonoscopy if they are deemed ineligible.

This solution fits seamlessly into existing practicing gastroenterologist workflows to support physician decision making and clinical trial patient recruitment.

Request More Information

Thank you for submitting!